Literature DB >> 19072652

Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Zuping Xia1, Christian Knaak, Jian Ma, Zanna M Beharry, Campbell McInnes, Wenxue Wang, Andrew S Kraft, Charles D Smith.   

Abstract

The Pim protein kinases are frequently overexpressed in prostate cancer and certain forms of leukemia and lymphoma. 5-(3-Trifluoromethylbenzylidene)thiazolidine-2,4-dione (4a) was identified by screening to be a Pim-1 inhibitor and was found to attenuate the autophosphorylation of tagged Pim-1 in intact cells. Although 4a is a competitive inhibitor with respect to ATP, a screen of approximately 50 diverse protein kinases demonstrated that it has high selectivity for Pim kinases. Computational docking of 4a to Pim-1 provided a model for lead optimization, and a series of substituted thiazolidine-2,4-dione congeners was synthesized. The most potent new compounds exhibited IC(50)s of 13 nM for Pim-1 and 2.3 microM for Pim-2. Additional compounds in the series demonstrated selectivities of more than 2500-fold and 400-fold for Pim-1 or Pim-2, respectively, while other congeners were essentially equally potent toward the two isozymes. Overall, these compounds are new Pim kinase inhibitors that may provide leads to novel anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072652      PMCID: PMC5404933          DOI: 10.1021/jm800937p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.

Authors:  Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

2.  Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.

Authors:  I Wayne Cheney; Shunqi Yan; Todd Appleby; Heli Walker; Todd Vo; Nanhua Yao; Robert Hamatake; Zhi Hong; Jim Z Wu
Journal:  Bioorg Med Chem Lett       Date:  2007-01-04       Impact factor: 2.823

3.  Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.

Authors:  Yong Xu; Tong Zhang; Hua Tang; Shumin Zhang; Min Liu; Dalin Ren; Yuanjie Niu
Journal:  J Surg Oncol       Date:  2005-12-15       Impact factor: 3.454

4.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Authors:  Abhinav Kumar; Valsan Mandiyan; Yoshihisa Suzuki; Chao Zhang; Julie Rice; James Tsai; Dean R Artis; Prabha Ibrahim; Ryan Bremer
Journal:  J Mol Biol       Date:  2005-04-22       Impact factor: 5.469

5.  Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.

Authors:  Kevin C Qian; Lian Wang; Eugene R Hickey; Joey Studts; Kevin Barringer; Charline Peng; Anthony Kronkaitis; Jun Li; Andre White; Sheenah Mische; Bennett Farmer
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

6.  Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety.

Authors:  Howard Bregman; Eric Meggers
Journal:  Org Lett       Date:  2006-11-23       Impact factor: 6.005

7.  Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells.

Authors:  M Lilly; A Kraft
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

8.  Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

Authors:  G Bruno; L Costantino; C Curinga; R Maccari; F Monforte; F Nicoló; R Ottanà; M G Vigorita
Journal:  Bioorg Med Chem       Date:  2002-04       Impact factor: 3.641

9.  The selectivity of inhibitors of protein kinase CK2: an update.

Authors:  Mario A Pagano; Jenny Bain; Zygmunt Kazimierczuk; Stefania Sarno; Maria Ruzzene; Giovanni Di Maira; Matthew Elliott; Andrzej Orzeszko; Giorgio Cozza; Flavio Meggio; Lorenzo A Pinna
Journal:  Biochem J       Date:  2008-11-01       Impact factor: 3.857

10.  Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas.

Authors:  G Selten; H T Cuypers; A Berns
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  40 in total

1.  Regulation of Skp2 levels by the Pim-1 protein kinase.

Authors:  Bo Cen; Sandeep Mahajan; Marina Zemskova; Zanna Beharry; Ying-Wei Lin; Scott D Cramer; Michael B Lilly; Andrew S Kraft
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  The Pim protein kinases regulate energy metabolism and cell growth.

Authors:  Zanna Beharry; Sandeep Mahajan; Marina Zemskova; Ying-Wei Lin; Baby G Tholanikunnel; Zuping Xia; Charles D Smith; Andrew S Kraft
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.

Authors:  Ke Ren; Wei Zhang; Yujun Shi; Jianping Gong
Journal:  Pathol Oncol Res       Date:  2009-10-12       Impact factor: 3.201

5.  Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Valentina Minieri; Marco De Dominici; Patrizia Porazzi; Samanta A Mariani; Orietta Spinelli; Alessandro Rambaldi; Luke F Peterson; Pierluigi Porcu; Marja T Nevalainen; Bruno Calabretta
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

6.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Authors:  Giorgio Cozza; Cristina Girardi; Alessandro Ranchio; Graziano Lolli; Stefania Sarno; Andrzej Orzeszko; Zygmunt Kazimierczuk; Roberto Battistutta; Maria Ruzzene; Lorenzo A Pinna
Journal:  Cell Mol Life Sci       Date:  2014-01-18       Impact factor: 9.261

7.  The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Authors:  Bo Cen; Ying Xiong; Jin H Song; Sandeep Mahajan; Rachel DuPont; Kristen McEachern; Daniel J DeAngelo; Jorge E Cortes; Mark D Minden; Allen Ebens; Alice Mims; Amanda C LaRue; Andrew S Kraft
Journal:  Mol Cell Biol       Date:  2014-04-28       Impact factor: 4.272

8.  Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.

Authors:  Bo Cen; Sandeep Mahajan; Wenxue Wang; Andrew S Kraft
Journal:  Cancer Res       Date:  2013-04-12       Impact factor: 12.701

9.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Authors:  Ying-Wei Lin; Zanna M Beharry; Elizabeth G Hill; Jin H Song; Wenxue Wang; Zuping Xia; Zhenhua Zhang; Peter D Aplan; Jon C Aster; Charles D Smith; Andrew S Kraft
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

10.  Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion.

Authors:  Niina M Santio; Riitta L Vahakoski; Eeva-Marja Rainio; Jouko A Sandholm; Sanna S Virtanen; Michelle Prudhomme; Fabrice Anizon; Pascale Moreau; Päivi J Koskinen
Journal:  Mol Cancer       Date:  2010-10-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.